BioNTech Financial Statements From 2010 to 2025

Stocks . USA . 
Stock . BioNTech SE
BNTX Stock  USD 98.96  1.90  1.88%   
BioNTech financial statements provide useful quarterly and yearly information to potential BioNTech SE investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on BioNTech financial statements helps investors assess BioNTech's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting BioNTech's valuation are summarized below:
Gross Profit
2.2 B
Profit Margin
(0.24)
Market Capitalization
24.2 B
Enterprise Value Revenue
2.0519
Revenue
2.8 B
We have found one hundred twenty available fundamental signals for BioNTech SE, which can be analyzed and compared to other ratios and to its rivals. All investors should make sure to validate all of BioNTech SE prevailing market performance against the performance between 2010 and 2025 to make sure the company can sustain itself down the road.

BioNTech Total Revenue

2.61 Billion

Check BioNTech financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among BioNTech's main balance sheet or income statement drivers, such as Net Interest Income of 446.2 M, Interest Income of 459.5 M or Discontinued Operations of 0.0, as well as many indicators such as Price To Sales Ratio of 9.02, Dividend Yield of 0.011 or PTB Ratio of 1.41. BioNTech financial statements analysis is a perfect complement when working with BioNTech Valuation or Volatility modules.
  
Check out the analysis of BioNTech Correlation against competitors.

BioNTech Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets23.7 B22.5 B7.2 B
Slightly volatile
Short and Long Term Debt Total175.4 M254.2 M110.6 M
Slightly volatile
Other Current Liabilities883.1 M1.8 B512 M
Slightly volatile
Total Current Liabilities1.5 B2.5 B870.7 M
Slightly volatile
Property Plant And Equipment Net1.2 B1.2 B365.9 M
Slightly volatile
Current Deferred Revenue192.7 M294.9 M123.1 M
Slightly volatile
Accounts Payable448 M426.7 M115.8 M
Slightly volatile
Cash10.2 B9.8 B3.2 B
Slightly volatile
Non Current Assets Total3.9 B3.7 B938.4 M
Slightly volatile
Cash And Short Term Investments17.6 B16.8 B4.5 B
Slightly volatile
Net Receivables2.9 B1.5 B1.6 B
Slightly volatile
Good Will399.6 M380.6 M82.7 M
Slightly volatile
Common Stock Total Equity185.2 M283.3 M129.3 M
Slightly volatile
Short Term Investments7.4 B7 B1.3 B
Slightly volatile
Liabilities And Stockholders Equity23.7 B22.5 B7.2 B
Slightly volatile
Non Current Liabilities Total409 M595.4 M347.7 M
Slightly volatile
Inventory204.3 M283.3 M118.5 M
Slightly volatile
Other Current Assets178 M212.7 M102.8 M
Slightly volatile
Total Liabilities1.9 B3.1 B1.2 B
Slightly volatile
Property Plant And Equipment Gross1.6 B1.5 B425.1 M
Slightly volatile
Total Current Assets9.6 B18.8 B5.6 B
Slightly volatile
Short Term Debt38.3 M39.5 M23.1 M
Slightly volatile
Intangible Assets829.9 M790.4 M196.7 M
Slightly volatile
Common Stock224.2 M285.9 M132.2 M
Slightly volatile
Net Working Capital9.1 B16.3 B4.7 B
Slightly volatile
Capital Stock261.5 M285.9 M219.3 M
Slightly volatile

BioNTech Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Interest Income459.5 M437.6 M100.6 M
Slightly volatile
Depreciation And Amortization312.9 M298 M73.2 M
Slightly volatile
Interest Expense15.7 M12.6 M8.4 M
Slightly volatile
Selling General Administrative271 M531.1 M150.1 M
Slightly volatile
Selling And Marketing Expenses36.8 M67.9 M21.9 M
Slightly volatile
Total Revenue2.6 B2.8 B2.9 B
Slightly volatile
Other Operating Expenses2.3 B4.1 B1.3 B
Slightly volatile
Research Development2.4 B2.3 B520.1 M
Slightly volatile
Cost Of Revenue514.2 M541.3 M744.5 M
Slightly volatile
Reconciled Depreciation312.9 M298 M73.2 M
Slightly volatile

BioNTech Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation59.2 M100.9 M33.2 M
Slightly volatile
Begin Period Cash Flow12.2 B11.7 B2.8 B
Slightly volatile
Depreciation312.9 M298 M73.2 M
Slightly volatile
Capital Expenditures269.1 M452.3 M164.4 M
Slightly volatile
End Period Cash Flow5.4 B9.8 B2.9 B
Slightly volatile
Change To Netincome1.5 B1.4 B438.6 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio9.029.498633.0841
Slightly volatile
Dividend Yield0.0110.01230.0134
Slightly volatile
Days Sales Outstanding11020287.4256
Slightly volatile
Stock Based Compensation To Revenue0.03480.03670.0793
Slightly volatile
Capex To Depreciation1.441.51783.9413
Slightly volatile
EV To Sales5.746.042630.8737
Slightly volatile
Inventory Turnover1.821.910717.3721
Slightly volatile
Days Of Inventory On Hand20119154.7388
Slightly volatile
Payables Turnover1.211.26865.4676
Slightly volatile
Sales General And Administrative To Revenue0.210.19310.2691
Slightly volatile
Research And Ddevelopement To Revenue1.010.81941.1299
Slightly volatile
Capex To Revenue0.160.16440.5876
Slightly volatile
Cash Per Share73.3169.815318.3934
Slightly volatile
Payout Ratio0.04030.04540.0495
Slightly volatile
Days Payables Outstanding302288165
Pretty Stable
Intangibles To Total Assets0.08480.0520.0594
Pretty Stable
Current Ratio4.077.45225.2245
Pretty Stable
Receivables Turnover1.721.80538.1084
Slightly volatile
Capex Per Share1.981.88140.747
Slightly volatile
Revenue Per Share17.9611.443812.4685
Slightly volatile
Interest Debt Per Share0.631.10980.5335
Slightly volatile
Debt To Assets0.01070.01130.0591
Slightly volatile
Graham Number11477.049.5107
Slightly volatile
Operating Cycle413393149
Slightly volatile
Days Of Payables Outstanding302288165
Pretty Stable
Dividend Payout Ratio0.04030.04540.0495
Slightly volatile
Ebt Per Ebit0.490.51561.2244
Slightly volatile
Long Term Debt To Capitalization0.01040.01090.1019
Slightly volatile
Total Debt To Capitalization0.01230.01293.2246
Very volatile
Quick Ratio3.997.345.1419
Pretty Stable
Cash Ratio2.683.86894.063
Slightly volatile
Days Of Inventory Outstanding20119154.7388
Slightly volatile
Days Of Sales Outstanding11020287.4256
Slightly volatile
Fixed Asset Turnover2.212.32474.6363
Slightly volatile
Debt Ratio0.01070.01130.0591
Slightly volatile
Price Sales Ratio9.029.498633.0841
Slightly volatile
Asset Turnover0.120.12210.2628
Pretty Stable

BioNTech Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap2.4 B2.6 B2.9 B
Slightly volatile
Enterprise Value3 B3 B2.8 B
Pretty Stable

BioNTech Fundamental Market Drivers

Forward Price Earnings7.0373
Cash And Short Term Investments16.8 B

BioNTech Upcoming Events

25th of March 2024
Upcoming Quarterly Report
View
13th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
25th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About BioNTech Financial Statements

BioNTech investors use historical fundamental indicators, such as BioNTech's revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in BioNTech. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue294.9 M192.7 M
Total Revenue2.8 B2.6 B
Cost Of Revenue541.3 M514.2 M
Stock Based Compensation To Revenue 0.04  0.03 
Sales General And Administrative To Revenue 0.19  0.21 
Research And Ddevelopement To Revenue 0.82  1.01 
Capex To Revenue 0.16  0.16 
Revenue Per Share 11.44  17.96 
Ebit Per Revenue(0.48)(0.45)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
VVisa Class A
CRMSalesforce
CRMSalesforce

Additional Tools for BioNTech Stock Analysis

When running BioNTech's price analysis, check to measure BioNTech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioNTech is operating at the current time. Most of BioNTech's value examination focuses on studying past and present price action to predict the probability of BioNTech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioNTech's price. Additionally, you may evaluate how the addition of BioNTech to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY